Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 05/26 10:14:59 pm
119.92 USD   +1.11%
05/26 CONCERT PHARMAC : CNCE) Asset Purchase Agreement With Vertex Pharmac..
05/24 VERTEX PHARMACE : Sports shorts
05/22 VERTEX PHARMACE : VRTX) Files An 8-K Other Events
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CEST

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
05/26 CONCERT PHARMACEUTICALS INC (NASDAQ : CNCE) Asset Purchase Agreement With Vertex..
05/25 VERTEX PHARMACEUTICALS INCORPORATED : Awards 40 Scholarships Totaling $200,000 t..
05/25 VERTEX PHARMACEUTICALS INCORPORATED : Maxor Selected as Limited Distribution Pro..
05/25 VERTEX PHARMACEUTICALS INCORPORATED : to Present at the UBS Healthcare Conferenc..
05/24 VERTEX PHARMACEUTICALS INCORPORATED : Sports shorts
05/22 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Other Events
05/22 VERTEX PHARMACEUTICALS INC / MA : Other Events (form 8-K)
05/19 VERTEX PHARMACEUTICALS INCORPORATED : Awards 40 Scholarships Totaling $200,000 t..
05/18 VERTEX PHARMACEUTICALS INCORPORATED : to Present at the UBS Healthcare Conferenc..
05/18 VERTEX PHARMACEUTICALS INCORPORATED : Vertex Pharmaceuticals' Shares Pop in Afte..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/22 FTC wants more info on Vertex's planned acquisition of Concert Pharma's CF ca..
05/17 FDA OKs expanded use of Vertex's CF med Kalydeco; shares ahead 1% after hours
05/16 Lessons From A Trump Presidency
05/15 Vertex Looking Forward To Cystic Fibrosis Phase 2 Readouts This Year
05/12 Best And Worst Performing S&P 500 Stocks YTD
Advertisement
Financials ($)
Sales 2017 2 222 M
EBIT 2017 476 M
Net income 2017 309 M
Finance 2017 890 M
Yield 2017 -
P/E ratio 2017 91,73
P/E ratio 2018 52,29
EV / Sales 2017 12,9x
EV / Sales 2018 10,7x
Capitalization 29 540 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 125 $
Spread / Average Target 5,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..59.90%29 540
AMGEN, INC.6.31%114 303
CELGENE CORPORATION0.86%91 153
GILEAD SCIENCES, INC.-9.85%84 362
REGENERON PHARMACEUTIC..24.83%48 437
ACTELION LTD26.30%31 070
More Results